COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,287 Articles (22,759 medRxiv, 8,528 bioRxiv)

Most recent first Previous |  Page 603: Articles 6021-6030  | Next

A spatio-temporal framework for modelling wastewater concentration during the COVID-19 pandemic
Li, G., Denise, H., Diggle, P., Grimsley, J., Holmes, C., James, D., Jersakova, R., Mole, C., Nicholson, G., Rangel Smith, C., Richardson, S., Rowe, W., Rowlingson, B., Torabi, F., Wade, M. J., Blangiardo, M.
10.1101/2022.10.14.22281081 — Posted: 2022-10-19
Effects of return-to-office, public schools reopening, and vaccination mandates on COVID-19 cases among municipal employee residents of New York City
Greene, S. K., Tabaei, B. P., Culp, G. M., Levin-Rector, A., Kishore, N., Baumgartner, J.
10.1101/2022.10.17.22280652 — Posted: 2022-10-19
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
Jittamala, P., Schilling, W. H. K., Watson, J. A., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P. J., Ekkapongpisit, M., Cruz, C., Callery, J. J., Boyd, S., Anunsittichai, O., Hongsuwan, M., Singhaboot, Y., Pagornrat, W., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M. Y., Keayarsa, S., Madmanee, W., Aguiar, R. S., Santos, F. M., Batty, E. M., Hanboonkunupakarn, P., Hanboonkunupakarn, B., Sookprome, S., Poovorawan, K., Imwong, M., Taylor, W. R., Chotivanich, V., Sangketchon, C., Ruksakul, W., Chotivanich, K., Pukrittayakamee, S., Dondorp, A. M., Day, N. P., Teixeira, M. M., Piyaphanee, W., Phumratanaprapin, W., White, N. J.
10.1101/2022.10.17.22281161 — Posted: 2022-10-19
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Schmidt, P., Narayan, K., Li, Y., Kaku, C., Brown, M., Champney, E., Geoghegan, J., Vasquez, M., Krauland, E., Yockachonis, T., Bai, S., Gunn, B., Cammarata, A., Rubino, C., Walker, L. M.
10.1101/2022.10.18.22281172 — Posted: 2022-10-19
Infection of primary nasal epithelial cells differentiates among lethal and seasonal human coronaviruses
Otter, C., Fausto, A., Tan, L. H., Cohen, N. A., Weiss, S. R.
10.1101/2022.10.17.512617 — Posted: 2022-10-18
Deep learning-based Drug discovery of Mac domain of SARS-CoV-2 (WT) Spike inhibitors: using experimental ACE2 Inhibition TR-FRET Assay Screening and Molecular Dynamic Simulations.
Iqbal, S., Lin, S. X.
10.1101/2022.10.17.512637 — Posted: 2022-10-18
N6-Adenosine Methylation of SARS-CoV-2 5-UTR Regulates Translation
Aly, A., Scott, G., Calderon, M., Haghighi, P.
10.1101/2022.10.17.512569 — Posted: 2022-10-18
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
Watanabe, S., Hama, R.
10.1101/2022.10.13.22281036 — Posted: 2022-10-18
Viral infectivity in pediatric SARS-CoV-2 clinical samples does not vary by age
Schmidt, M. M., Despres, H. W., Shirley, D. J., Bose, M. E., McCaul, K. C., Crothers, J. W., Henrickson, K. J., Lee, B., Bruce, E. A.
10.1101/2022.10.17.22281193 — Posted: 2022-10-18
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
McCarthy, M. W., Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Felker, G. M., Jayaweera, D., Sulkowski, M., Gentile, N., Bramante, C., Singh, U., Dolor, R. J., Ruiz-Unger, J., Wilson, S., DeLong, A., Remaly, A., Wilder, R., Collins, S., Dunsmore, S. E., Adam, S. J., Thicklin, F., Hanna, G., Ginde, A. A., Castro, M., McTigue, K., Shenkman, E., Hernandez, A. F.
10.1101/2022.10.17.22281178 — Posted: 2022-10-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).